BibTex RIS Cite

The Relationship Between Anti-HBs Values-Seroprotective Ratio of HBV Vaccine And Age-Gender In Children

Year 2012, , 131 - 135, 01.09.2012
https://doi.org/10.5505/sakaryamj.2012.40427

Abstract

Objective: The study was aimed to investigate the relationship between seroprotective ratio-Anti-HBs values of HBV vaccine and age-gender in children.Method: Seven months and older-aged 143 children who underwent a three-dose HBV vaccination schedule were included in the study with family consent. Children having the last vaccination within the last month were excluded. Children were divided into 4 groups: 7-24 months, 25-48 months, 49-60 months and above 61 months. HBsAg and Anti-HBs levels were determined in all cases. Results: The seroprotective ratio of Anti-HBs values of the patients with the mean age of 73.09 months was detected as %80.14. The average values for Anti-HBs were 134.8 mIU/mL for male and 154.5 mIU/mL for female patients. No statistically significant difference between age gorups and sexes in terms of Anti-HBs positivity was observed.Conclusion: Immunization activities should be continued without interruption and the vaccination efficacy should be monitored consistently by studies

References

  • By K. E. Nelson, C. Williams, and N. Graham., Infectious Disease Epidemiology: Theory and Practice, July 15, 2000;:907-21.
  • World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2000). WHO 4 Web site. 2000. http://who.int/inf-fs/en/fact204.html.
  • Core Information For The Development of Immunization Policy: 2002 Update. Hepatitis B vaccine.WHO/V and B/02.28. sy: 39-44, ve World Health Organization. Hepatitis B.
  • Hans Hsienhong Lin, Li-Yu Wang Vaccination for Hepatitis B Tzu Chi Med J 2005_17_No. 5303-9.
  • Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346(22): 1682–3.
  • Jinlin Hou, Zhihua Liu, and Fan Gu.Epidemiology and Prevention of Hepatitis B Virus InfectionInt. J. Med. Sci. 2005 2(1):50-7.
  • Blumberg BS 1997. Hepatites B virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sci USA 94: 7121-5.
  • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
  • Dr. Selma Yegane Tosun Ülkemizde Hepatit B Aşılaması sted 2002 cilt 11 sayı 4 140.
  • Alter M. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39:64-9.
  • Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-52.
  • Stephen J. McPhee, Thoa Nguyen, Gary L. Euler, Jeremiah Mock, Ching Wong, Tram Lam, Walter Nguyen, Sang Nguyen, Martin Quach Huynh Ha, Son T. Do and Chau Buu Successful Promotion of Hepatitis B Vaccinations Among Vietnamese- American Children Ages 3 to 18: Results of a Controlled Trial PEDIATRICS Vol. 111 No. 6 June 2003 1278-88.
  • Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94(2): 153–6.
  • Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Br Med J 2002; 325:569.
  • Kurt M, Tayfur Ö, Harmancı Ö, Batman F. Gebelikle ilgili karaciğer hastalıkları. Hacettepe Tıp Dergisi 2005; 36:53-64.
  • Bernard PH. Hepatit Band C Virolojikal Tests: Interpretation and practical results in women. Gynecol Obstet Fertil 2005 Jun; 33(6):423-8.
  • Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies.Gastroenterology 2007:132(4):1287-93.
  • http://asidanisma.com/2011_asi_semalari_01p.asp.
  • Metehan Özen, Saim Yoloğlu, Yüksel Işık , Gülay Yetkin Turgut Özal Tıp Merkezi’ne başvuran 0-16 yaş grubu çocuklarda AntiHBs seropozitifliği Türk Pediatri Arşivi 2006; 41:31-5.
  • Demirören K, Deveci U, Demirören S. Sağlık Bakanlığımızın uyguladığı hepatit B aşılarının sağladığı Anti HBs değerleri. F.Ü.Sağ. Bil. Derg 2007: 21(5): 183-5.
  • Nalbantoğlu B, Nalbantoğlu A, Külcü NU, Say A. 9 ay 8 yaş arası çocuklarda Hepatit B seroprevalansı ve aşılama durumları. Çocuk Dergisi 10(3):116-121,2010.
  • Yazdanpanah P, Safari M, Yazdanpanah S. Persistence of HBV vaccine’s protection and response to hepatitis B booster immunization in 5- to 7-year-old children in the Kohgiloyeh and Boyerahmad province, Iran. Hepatitis Monthly 2010; 10(1):17-21.
  • Hans Hsienhong Lin, Li-Yu Wang. Vaccination for Hepatitis B. Tzu Chi Med J 2005; 17: 303-9.
  • Metodi J, Aboud S, Mpembeni R, Munubhi E. Immunity to hepatitis B vaccine in Tanzanian under-5 children. Ann Trop Paediatr. 2010;30(2):129-36.
  • Mast E, Mahoney F, Kane M, Margolis H: Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 2004, pp 299-337.
  • A.Jafarzadeh, M.A. Shokrgozar, J. Khoshnoodi, F. Shokri. Unresponsiveness to Recombinant Hepatitis B Vaccine in Healthy Iranian Neonates:Association with HLA Antigens IJMS Vol 27, No.2, June 2002 51-5.
  • Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Longterm immunogenecity and efficacy of universal hepatitis B vaccination in Taiwan. J Infect Dis 2003; 187: 134- 8.

Çocuklarda HBV Aşısının Koruyuculuk Oranı ve Anti-HBs Değerlerinin Yaş ve Cinsiyet İle Olan İlişkisi

Year 2012, , 131 - 135, 01.09.2012
https://doi.org/10.5505/sakaryamj.2012.40427

Abstract

Amaç: Bu çalışmada çocuklarda HBV aşısının koruyuculuk oranı ve Anti-HBs değerlerinin yaş ve cinsiyet ile olan ilişkisinin araştırılması planlanmıştır.Materyal-Metod: Üç dozluk HBV aşı şeması uygulanmış olan 7 aydan büyük 143 çocuk aile onamları alınarak çalışmaya dahil edildi. Son aşıdan sonra en az 1 ay süre geçmeyen çocuklar çalışma dışı bırakıldı. Çocuklar 7-24 ay 25-48 ay, 49-60 ay ve 61 ay üstü olmak üzere 4 gruba ayrıldı. Tüm vakaların HBsAg ve Anti-HBs düzeylerine bakıldı.Bulgular: Yaş ortalaması 73.09 ay olan hastaların Anti-HBs değerlerinin seroprotektif oranı %80.14 olarak saptandı. Ortalama Anti-HBs değeri erkeklerde 134.8 mIU/mL, kızlarda 154.5 mIU/mL bulundu. Yaş grupları ve cinsiyetler arasında Anti-HBs pozitifliği bakımından istatistiksel anlamlı bir fark saptanmadı. Sonuç: Aşılama faaliyetlerine kesintisiz olarak devam edilmeli, aşılama etkinliği yapılacak çalışmalarla sürekli izlenmelidir

References

  • By K. E. Nelson, C. Williams, and N. Graham., Infectious Disease Epidemiology: Theory and Practice, July 15, 2000;:907-21.
  • World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2000). WHO 4 Web site. 2000. http://who.int/inf-fs/en/fact204.html.
  • Core Information For The Development of Immunization Policy: 2002 Update. Hepatitis B vaccine.WHO/V and B/02.28. sy: 39-44, ve World Health Organization. Hepatitis B.
  • Hans Hsienhong Lin, Li-Yu Wang Vaccination for Hepatitis B Tzu Chi Med J 2005_17_No. 5303-9.
  • Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346(22): 1682–3.
  • Jinlin Hou, Zhihua Liu, and Fan Gu.Epidemiology and Prevention of Hepatitis B Virus InfectionInt. J. Med. Sci. 2005 2(1):50-7.
  • Blumberg BS 1997. Hepatites B virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sci USA 94: 7121-5.
  • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
  • Dr. Selma Yegane Tosun Ülkemizde Hepatit B Aşılaması sted 2002 cilt 11 sayı 4 140.
  • Alter M. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39:64-9.
  • Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-52.
  • Stephen J. McPhee, Thoa Nguyen, Gary L. Euler, Jeremiah Mock, Ching Wong, Tram Lam, Walter Nguyen, Sang Nguyen, Martin Quach Huynh Ha, Son T. Do and Chau Buu Successful Promotion of Hepatitis B Vaccinations Among Vietnamese- American Children Ages 3 to 18: Results of a Controlled Trial PEDIATRICS Vol. 111 No. 6 June 2003 1278-88.
  • Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94(2): 153–6.
  • Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Br Med J 2002; 325:569.
  • Kurt M, Tayfur Ö, Harmancı Ö, Batman F. Gebelikle ilgili karaciğer hastalıkları. Hacettepe Tıp Dergisi 2005; 36:53-64.
  • Bernard PH. Hepatit Band C Virolojikal Tests: Interpretation and practical results in women. Gynecol Obstet Fertil 2005 Jun; 33(6):423-8.
  • Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies.Gastroenterology 2007:132(4):1287-93.
  • http://asidanisma.com/2011_asi_semalari_01p.asp.
  • Metehan Özen, Saim Yoloğlu, Yüksel Işık , Gülay Yetkin Turgut Özal Tıp Merkezi’ne başvuran 0-16 yaş grubu çocuklarda AntiHBs seropozitifliği Türk Pediatri Arşivi 2006; 41:31-5.
  • Demirören K, Deveci U, Demirören S. Sağlık Bakanlığımızın uyguladığı hepatit B aşılarının sağladığı Anti HBs değerleri. F.Ü.Sağ. Bil. Derg 2007: 21(5): 183-5.
  • Nalbantoğlu B, Nalbantoğlu A, Külcü NU, Say A. 9 ay 8 yaş arası çocuklarda Hepatit B seroprevalansı ve aşılama durumları. Çocuk Dergisi 10(3):116-121,2010.
  • Yazdanpanah P, Safari M, Yazdanpanah S. Persistence of HBV vaccine’s protection and response to hepatitis B booster immunization in 5- to 7-year-old children in the Kohgiloyeh and Boyerahmad province, Iran. Hepatitis Monthly 2010; 10(1):17-21.
  • Hans Hsienhong Lin, Li-Yu Wang. Vaccination for Hepatitis B. Tzu Chi Med J 2005; 17: 303-9.
  • Metodi J, Aboud S, Mpembeni R, Munubhi E. Immunity to hepatitis B vaccine in Tanzanian under-5 children. Ann Trop Paediatr. 2010;30(2):129-36.
  • Mast E, Mahoney F, Kane M, Margolis H: Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 2004, pp 299-337.
  • A.Jafarzadeh, M.A. Shokrgozar, J. Khoshnoodi, F. Shokri. Unresponsiveness to Recombinant Hepatitis B Vaccine in Healthy Iranian Neonates:Association with HLA Antigens IJMS Vol 27, No.2, June 2002 51-5.
  • Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Longterm immunogenecity and efficacy of universal hepatitis B vaccination in Taiwan. J Infect Dis 2003; 187: 134- 8.
There are 27 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Mehmet Balcı This is me

Öznur Küçük This is me

Yalçın Erdoğan This is me

Hayrullah Yazar This is me

Özgür Satılmış This is me

Mehmet Uyar This is me

Neziha Yılmaz This is me

Publication Date September 1, 2012
Submission Date September 7, 2015
Published in Issue Year 2012

Cite

AMA Balcı M, Küçük Ö, Erdoğan Y, Yazar H, Satılmış Ö, Uyar M, Yılmaz N. Çocuklarda HBV Aşısının Koruyuculuk Oranı ve Anti-HBs Değerlerinin Yaş ve Cinsiyet İle Olan İlişkisi. Sakarya Tıp Dergisi. September 2012;2(3):131-135. doi:10.5505/sakaryamj.2012.40427

30703

SMJ'de yayınlanan makaleler, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı kapsamında lisanslanır